Disintegrin variants that bind specifically to one or more of a5ß1 and av integrins, such as a?ß1, a?ß3, a?ß5, a?ß6 and a?ß8, but with reduced binding activity to aIIbß3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an av integrin or an a5ß1 integrin.